Year: 2024
Type: article
Abstract: Aging poses a burgeoning challenge in the modern world, as increasing life expectancies and shifting demographics contribute to a growing elderly population. In the intricate drama of aging, senescent cells (SNCs) play a chilling role akin to ‘zombie cells’ in horror movies. They refuse to die, instead wreaking havoc by secreting detrimental substances that can harm neighbouring cells. Their persistent presence, much like relentless zombies, leads to a decline in tissue function and is closely associated with various age-related diseases.1 As age advances, SNCs accumulate in our body organs comprising the cardiovascular system. Notably, these cells stimulate pro-survival pathways and hinder their regenerative capacity. Given the limited proliferative potential of cardiomyocytes and vascular endothelial cells, the accumulation of these SNCs accelerates the deterioration of cardiovascular regeneration. This issue is exacerbated by the fact that cardiovascular diseases (CVD) manifest a significant health concern among the aging population. Cellular senescence can be triggered by a myriad of factors, including chronic oxidative stress, telomere attrition, DNA instability, and metabolic imbalances.2 Moreover, specific secretomes can induce senescence through the activation of the senescence-associated secretory phenotype (SASP), leading to a chronic inflammatory microenvironment. Disrupted signalling pathways, such as the p16INK4a-p19INK4d and p53-p21WAF1/Cip1 pathways and the mammalian target of rapamycin (mTOR) that promote proliferative arrest, play pivotal roles in mediating senescence in the cardiovascular system.3 For instance, artificial removal of p16INK4a-expressing SNCs from INK-ATTAC transgenic mice or Ldlr−/−;3MR mice delayed aging-related phenotypes, including cardiac arrhythmias, arterial stiffening, and atherosclerosis.2,4 Recognition of senescence hallmarks has spurred investigations into genetic and pharmacological interventions targeting key pathways, including the SASP and apoptosis, in an effort to preserve cardiovascular health and extend lifespan. Pharmacological senotherapies primarily fall into two categories: senolytics, which differentially eliminate SNCs, and senomorphics, which neutralize the detrimental SASP to induce senostasis5 (Figure 1). These therapies show promise in mitigating age-related cardiovascular impairments. Nonetheless, it is crucial to execute senostasis or SNC removal with caution, as injury-induced senescence at a transient state, but not a prolonged state, positively influences the reparative milieu of the heart and vasculature. Cardiovascular senescent cell features targeted by senolytics and senomorphics. Schematic illustration of cellular senescence hallmarks in the aging cardiovascular system. Multiple drivers of cellular senescence activate pro-survival senescent cell anti-apoptotic pathway networks while stimulating cell cycle arrest signals. Senolytics are employed to target senescent cell anti-apoptotic pathway and other survival networks, as well as proliferative arrest pathways, effectively eliminating cardiovascular senescent cells. Senomorphic compounds target pathological senescence-associated secretory phenotype signalling, either preventing the production or neutralizing senescence-associated secretory phenotype components in senescent cells (images created with BioRender.com) The application of senolytics for cardiovascular rejuvenation emerged as a revolutionary concept in the early 21st century. This therapeutic approach has exhibited promise in various preclinical studies, offering hope for potential revitalizing cardiovascular system in aging. Recent discoveries propose a number of mechanistic nodes for senolytics that potentially alleviate chronic cardiovascular conditions such as atherosclerosis, cardiac fibrosis, and hypertension. The majority of senolytics identified to date selectively eliminate SNCs by disrupting senescent cell anti-apoptotic pathway (SCAP) pro-survival pathways such as p53-p21WAF1/Cip1 and BCL-2 family proteins, which are upregulated in SNCs.3 The heterogeneity in senolysis at the single-cell level among various types of SNCs has prompted researchers to explore specific senolytics that function effectively in the aging cardiovascular system.4 The first reported senolytic was a combination of dasatinib (D), an FDA-approved anti-cancer drug, and quercetin (Q), a natural flavonoid, that targets SCAP, including BCL-2, p21WAF1/Cip1, and PI3K.5 In a mouse model of atherosclerosis, D + Q reduced plaque burden and improved vascular function by selectively eliminating SNCs from atherosclerotic lesions.6 Additionally, D + C improved age-related cardiac dysfunction by rescuing endothelial senescence-induced denervation in aged mice.7 In patients with heart failure with preserved ejection fraction (HFpEF), the most common form of HF in the elderly, D + Q improved cardiac function and exercise capacity.6 Subsequent research has explored additional compounds with similar properties, including BCL-2 family inhibitors, HSP90 inhibitors, p53 pathway–targeting compounds (such as FOXO4-p53, MDM2/p53, or USP7 inhibitors), and natural products for clearing SNCs.3 However, not all of these compounds have been tested for their senolytic effects in the cardiovascular system. Among them, navitoclax, a BCL-2 family inhibitor, FOXO4-DRI, a FOXO4-p53–targeting peptide, and fisetin, an herbal flavonoid, have demonstrated potential as senolytic agents in preclinical models of heart failure with reduced ejection fraction (HFrEF), myocardial infarction, and atherosclerosis.4,6 While senolytics hold promise in ameliorating aging-associated diseases (AAD), the challenges lie in identifying senescence biomarkers and their off-target effects. Researchers are now looking into developing second-generation senolytics to more selectively target SNCs.8 One biomarker considered as the gold standard in detecting cellular senescence is the lysosomal senescence-associated β-galactosidase (SA-β-gal).2 An innovative pro-drug design comprising a cytotoxic compound capped with galacto-oligosaccharides, a substrate of SA-β-gal, could evolve the first-generation senolytics to selectively kill only SNCs.5 Another biomarker is imbalanced proteostasis, which occurs following the accumulation of misfolded protein oligomers in SNCs. Patients with ischaemic heart disease, cardiomyopathies, or atherosclerosis manifest aberrant misfolded protein aggregation and activation of unfolded protein responses (UPR) in cardiac and vascular cells.9 This knowledge opened an avenue for the innovative proteolysis-targeting chimaera (PROTAC) technology to specifically degrade misfolded proteins. To date, PROTACs have been successfully applied in chemotherapy–senolytic combinational strategy and in neurodegenerative diseases.5 However, it is not surprising that more PROTAC senolytics will be identified in other AAD including CVD in the future. Additional pharmacokinetic/pharmacodynamic studies will be essential to ensure their sufficient absorption and efficacy in cardiovascular cells in vivo. In addition to senolytics, senomorphics offer an alternative pharmacological senotherapy that not only suppresses the senescence-messaging inflammatory secretome but also mitigates the establishment of a senescent microenvironment. Foremost among these are the mTOR inhibitors, including rapamycin or its analogues, known for efficiently suppressing the SASP.4,5 Consequently, it is expected to exhibit anti-aging activity in the heart and vasculature in human and murine models. Moreover, rapamycin dampens the SASP and prevents premature senescence in aging human cardiac stem cells (CSC), thereby supporting cardiac regeneration.5 Similarly, metformin, a first-line anti-diabetic drug, downregulates the expression of SASP components in diverse SNCs, extending healthspan and lifespan across species.5 While the senomorphic effects and mechanisms of metformin remain to be fully tested in aged organisms, it has demonstrated the ability to rescue premature cardiac and endothelial senescence in doxorubicin-exposed mice.6 Similar to senolytics, the challenge lies in dealing with non-specific and off-target effects, a major hurdle for their utilization within senotherapeutic regimens.8 Additionally, characterizing the optimal timing and treatment duration for maximal suppression of SNCs remains an unmet need. Other promising alternatives are natural compounds such as resveratrol that stimulates SIRT1, a NAD+-dependent deacetylase, activation of which represses genes involved in SASP-mediated responses. Resveratrol rescued resident CSC senescence and restored their reparative capacity in mice with doxorubicin-induced cardiomyopathy.6,9 In this regard, we have recently identified omega-3 alpha-linolenic acid to upregulate SIRT1 and thereby counteract SASP in aortic endothelial cells, alleviating arterial stiffness and aortic dysfunction.10 Other NAD+ boosters include nicotinamide riboside (NR) or nicotinamide mononucleotide that improve functional phenotypes with aging, such as skeletal muscle strength and exercise, or chronic disease such as atherosclerosis. Downstream targets of these NAD+ boosters may also serve as targets for therapy. For example, the NR-mediated effects of targeting the lncRNA SNHG12 reduced vascular senescence and atherosclerosis.11 Circulating levels of SIRT1 decrease with age, predicting higher risk for major cardiovascular events in humans. Thus, SIRT1 stimulation or supplementation with its cofactor NAD+ as SASP-neutralizing signals warrants further investigations. In conclusion, the removal of SNCs holds promise to pave the way for mitigating cardiovascular risk among the elderly. This approach is expected to become increasingly personalized, precise, and integrated with other anti-aging strategies. The future of drug repurposing approaches provides opportunities for drug discovery in the context of cardiovascular aging. The development of new generations of senolytics and senomorphics will be fostered by selectively targeting senescence biomarkers or key downstream mediators, utilizing novel drug delivery strategies, and integrating single-cell multi-omics approaches. These efforts coupled with proof-of-concept clinical trials that examine effects of candidate therapies on focused age-associated functional phenotypes will significantly advance the field. All authors declare no disclosure of interest for this contribution.
Source: European Heart Journal
Language: English
Subfield: Cell Biology
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W4390675357
